Lung Cancer (LNCR)

Categories: Cancer diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer

MalaCards integrated aliases for Lung Cancer:

Name: Lung Cancer 56 12 74 25 73 29 6 42 3 15
Non-Small Cell Lung Cancer 12 74 36 29 6 15
Non-Small Cell Lung Carcinoma 12 15 17 71
Lung Carcinoma 12 54 15 17
Lung Cancer, Protection Against 56 29 6
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in 56 13
Lung Cancer, Susceptibility to 56 6
Malignant Neoplasm of Lung 25 71
Nonsmall Cell Lung Cancer 56 73
Alveolar Cell Carcinoma 73 29
Carcinoma of Lung 12 71
Lung Neoplasms 25 71
Lung Neoplasm 12 74
Nsclc 12 54
Nonsmall Cell Lung Cancer, Response to Tyrosine Kinase Inhibitor in 56
Nonsmall Cell Lung Cancer, Susceptibility to 56
Nonsmall Cell Lung Cancer, Somatic 56
Primary Malignant Neoplasm of Lung 71
Bronchioloalveolar Adenocarcinoma 71
Adenocarcinoma of Lung, Somatic 56
Carcinoma, Non-Small-Cell Lung 43
Lung Non-Small Cell Carcinoma 12
Carcinoma Non-Small Cell Lung 54
Cancer, Lung, Non-Small Cell 39
Lung Cancer, Resistance to 56
Malignant Tumor of Lung 25
Adenocarcinoma of Lung 73
Lung Malignant Tumors 25
Respiratory Carcinoma 25
Lung Cancer, Somatic 56
Malignant Lung Tumor 25
Pulmonary Carcinoma 25
Pulmonary Neoplasms 25
Cancer of Bronchus 25
Cancer of the Lung 25
Lung Malignancies 25
Pulmonary Cancer 25
Neoplasm of Lung 29
Lung Carcinomas 15
Cancer of Lung 12
Lung Cancers 15
Cancer, Lung 39
Cancer Lung 54
Lncr 73



somatic mutation
autosomal dominant

genes associated with susceptibility to lung cancer, e.g., faslg , fas , chrna5 , chrna3
genes associated with a protection against lung cancer, e.g., casp8 , cyp2a6
mutations in egfr (131550) are associated with altered response to treatment with tyrosine kinase inhibitors


External Ids:

Disease Ontology 12 DOID:1324 DOID:3905 DOID:3908
OMIM 56 211980
KEGG 36 H00014
NCIt 49 C2926 C4878
UMLS 71 C0007120 C0007131 C0024121 more

Summaries for Lung Cancer

Genetics Home Reference : 25 Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasizes) into other tissues. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked. Lung cancer is generally divided into two types, small cell lung cancer and non-small cell lung cancer, based on the size of the affected cells when viewed under a microscope. Non-small cell lung cancer accounts for 85 percent of lung cancer, while small cell lung cancer accounts for the remaining 15 percent. Small cell lung cancer grows quickly and in more than half of cases the cancer has spread beyond the lung by the time the condition is diagnosed. Small cell lung cancer often metastasizes, most commonly to the liver, brain, bones, and adrenal glands (small hormone-producing glands located on top of each kidney). After diagnosis, most people with small cell lung cancer survive for about 1 year; less than seven percent survive 5 years. Non-small cell lung cancer is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. Adenocarcinoma arises from the cells that line the small air sacs (alveoli) located throughout the lungs. Squamous cell carcinoma arises from squamous cells that line the passages leading from the windpipe (trachea) to the lungs (bronchi). Large cell carcinoma arises from epithelial cells that line the lungs. Large cell carcinoma encompasses non-small cell lung cancers that do not appear to be adenocarcinomas or squamous cell carcinomas. The 5-year survival rate for people with non-small cell lung cancer is usually between 11 and 17 percent; it can be lower or higher depending on the subtype and stage of the cancer.

MalaCards based summary : Lung Cancer, also known as non-small cell lung cancer, is related to lung cancer susceptibility 3 and small cell cancer of the lung, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Lung Cancer is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Non-small cell lung cancer and MicroRNAs in cancer. The drugs Iodine and Terbutaline have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and breast, and related phenotypes are alveolar cell carcinoma and Decreased viability

Disease Ontology : 12 A respiratory system cancer that is located in the lung.

OMIM : 56 Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are nonsmall cell lung cancer and small cell lung cancer (see 182280), which account for 85% and 15% of all lung cancers, respectively. Nonsmall cell lung cancer can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. Cigarette smoking causes all types of lung cancer, but it is most strongly linked with small cell lung cancer and squamous cell carcinoma. Adenocarcinoma is the most common type in patients who have never smoked. Nonsmall cell lung cancer is often diagnosed at an advanced stage and has a poor prognosis (summary by Herbst et al., 2008). (211980)

MedlinePlus : 42 Lung cancer is one of the most common cancers in the world. It is a leading cause of cancer death in men and women in the United States. Cigarette smoking causes most lung cancers. The more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. High levels of pollution, radiation and asbestos exposure may also increase risk. Common symptoms of lung cancer include A cough that doesn't go away and gets worse over time Constant chest pain Coughing up blood Shortness of breath, wheezing, or hoarseness Repeated problems with pneumonia or bronchitis Swelling of the neck and face Loss of appetite or weight loss Fatigue Doctors diagnose lung cancer using a physical exam, imaging, and lab tests. Treatment depends on the type, stage, and how advanced it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

CDC : 3 Cancer is a disease in which cells in the body grow out of control. When cancer starts in the lungs, it is called lung cancer. Lung cancer begins in the lungs and may spread to lymph nodes or other organs in the body, such as the brain. Cancer from other organs also may spread to the lungs. When cancer cells spread from one organ to another, they are called metastases. Lung cancers usually are grouped into two main types called small cell and non-small cell. These types of lung cancer grow differently and are treated differently. Non-small cell lung cancer is more common than small cell lung cancer.

KEGG : 36 Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer and represents a heterogeneous group of cancers, consisting mainly of squamous cell (SCC), adeno (AC) and large-cell carcinoma. Molecular mechanisms altered in NSCLC include activation of oncogenes, such as K-RAS, EGFR and EML4-ALK, and inactivation of tumorsuppressor genes, such as p53, p16INK4a, RAR-beta, and RASSF1. Point mutations within the K-RAS gene inactivate GTPase activity and the p21-RAS protein continuously transmits growth signals to the nucleus. Mutations or overexpression of EGFR leads to a proliferative advantage. EML4-ALK fusion leads to constitutive ALK activation, which causes cell proliferation, invasion, and inhibition of apoptosis. Inactivating mutation of p53 can lead to more rapid proliferation and reduced apoptosis. The protein encoded by the p16INK4a inhibits formation of CDK-cyclin-D complexes by competitive binding of CDK4 and CDK6. Loss of p16INK4a expression is a common feature of NSCLC. RAR-beta is a nuclear receptor that bears vitamin-A-dependent transcriptional activity. RASSF1A is able to form heterodimers with Nore-1, an RAS effector.Therefore loss of RASSF1A might shift the balance of RAS activity towards a growth-promoting effect.

UniProtKB/Swiss-Prot : 73 Lung cancer: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

Wikipedia : 74 Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell... more...

Related Diseases for Lung Cancer

Diseases in the Lung Cancer family:

Lung Carcinoma in Situ

Diseases related to Lung Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1868)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 37.9 PTEN PRKN PIK3CA NRAS MIR17 MAP2K1
2 small cell cancer of the lung 35.9 PTEN PIK3CA KIT EGFR
3 lung squamous cell carcinoma 35.4 PTEN PIK3CA KRAS EGFR BRAF ALK
4 adenocarcinoma 35.0 PTEN PIK3CA MAP2K1 KRAS KIT ERBB2
5 colorectal cancer 34.8 PTEN PPP2R1B PIK3CA NRAS MIR17 MAP2K1
6 endometrial cancer 34.8 PTEN PIK3CA NRAS KRAS KIT ERBB2
7 breast cancer 34.7 SLC22A18 PTEN PIK3CA NRAS MIR17 MAP2K1
8 gastric cancer 34.4 PTEN PIK3CA NRAS MIR17 MAP2K1 KRAS
9 hepatocellular carcinoma 34.2 PTEN PIK3CA NRAS MIR17 MAP2K1 KRAS
10 neuroblastoma 34.2 PTEN PRKN PIK3CA NRAS MIR17 MAP2K1
11 ovarian cancer 34.1 PTEN PRKN PIK3CA MIR17 MAP2K1 KRAS
12 small cell carcinoma 34.0 PTEN KRAS KIT EGFR ALK
13 bladder cancer 34.0 PTEN PIK3CA NRAS MIR17 MAP2K1 KRAS
14 leukemia, acute myeloid 34.0 PTEN NRAS MIR17 MAP2K1 KRAS KIT
15 myeloma, multiple 33.9 PTEN NRAS MIR17 KRAS KIT FASLG
16 squamous cell carcinoma 33.9 PTEN PIK3CA MAP2K1 ERBB2 EGFR BRAF
17 in situ pulmonary adenocarcinoma 33.9 KRAS EGFR ALK
18 glioblastoma multiforme 33.8 PTEN PIK3CA NRAS MAP2K1 KRAS KIT
19 melanoma 33.8 PTEN PIK3CA NRAS MIR17 MAP2K1 KRAS
20 pancreatic cancer 33.8 PTEN PIK3CA MIR17 MAP2K1 KRAS FASLG
21 renal cell carcinoma, nonpapillary 33.7 PTEN PIK3CA NRAS MIR17 KIT FASLG
22 large cell carcinoma 33.7 KRAS KIT ERBB2 EGFR
23 exanthem 33.6 KRAS KIT ERBB2 EGFR
24 leukemia, chronic lymphocytic 33.6 PTEN NRAS MIR17 KRAS KIT ERBB2
25 lymphoma 33.4 PIK3CA NRAS KIT EGFR CASP8 BRAF
26 esophageal cancer 33.4 PTEN PIK3CA KRAS FASLG ERBB2 EGFR
27 gastric adenocarcinoma 33.3 PTEN PIK3CA NRAS KRAS KIT FASLG
28 cervical cancer 33.3 PTEN PPP2R1B PIK3CA MIR17 IRF1 FASLG
29 adenosquamous carcinoma 33.3 PTEN PIK3CA KRAS KIT EGFR
30 squamous cell carcinoma, head and neck 33.2 PTEN PIK3CA MIR17 FASLG ERCC6 ERBB2
31 medulloblastoma 33.2 PTEN PIK3CA NRAS MIR17 MAP2K1 KIT
32 pancreatic adenocarcinoma 33.2 PTEN PIK3CA MAP2K1 KRAS KIT FASLG
33 sarcoma 33.2 PIK3CA NRAS MAP2K1 KRAS KIT CASP8
34 myelodysplastic syndrome 33.2 PTEN NRAS KRAS KIT IRF1 FASLG
35 brain cancer 33.1 PTEN PIK3CA NRAS MIR17 EGFR CASP8
36 leukemia 33.0 NRAS KRAS KIT IRF1 ERBB2 BRAF
37 in situ carcinoma 33.0 PTEN MIR17 ERBB2 EGFR
38 prostate cancer 33.0 PTEN PIK3CA MIR17 MAP2K1 KRAS FASLG
39 leukemia, chronic myeloid 33.0 PTEN NRAS MIR17 KRAS KIT ERBB2
40 lymphoma, non-hodgkin, familial 32.9 PTEN PIK3CA NRAS MIR17 CASP8 BRAF
41 large cell neuroendocrine carcinoma 32.8 KIT ERBB2 EGFR ALK
42 adenoid cystic carcinoma 32.8 PTEN PIK3CA KRAS KIT ERBB2 EGFR
43 bladder urothelial carcinoma 32.8 PTEN PIK3CA NRAS MAP2K1 KRAS KIT
44 bronchiolo-alveolar adenocarcinoma 32.8 MIR17 KRAS EGFR
45 thyroid gland cancer 32.8 PTEN PIK3CA NRAS MIR17 MAP2K1 KRAS
46 gastrointestinal stromal tumor 32.8 PTEN KRAS KIT ERBB2 EGFR CASP8
47 rhabdomyosarcoma 32.8 SLC22A18 PTEN MAP2K1 KRAS KIT EGFR
48 thyroid carcinoma 32.8 PTEN PIK3CA NRAS BRAF
49 mucinous adenocarcinoma 32.7 KRAS KIT ERBB2 EGFR ALK
50 colon adenocarcinoma 32.7 PTEN PIK3CA KRAS FASLG ERBB2 EGFR

Graphical network of the top 20 diseases related to Lung Cancer:

Diseases related to Lung Cancer

Symptoms & Phenotypes for Lung Cancer

Human phenotypes related to Lung Cancer:

# Description HPO Frequency HPO Source Accession
1 alveolar cell carcinoma 31 HP:0006519

Symptoms via clinical synopsis from OMIM:

Respiratory Lung:
alveolar cell carcinoma
nonsmall cell lung cancer
adenocarcinoma of lung

alveolar cell carcinoma
nonsmall cell lung cancer
adenocarcinoma of lung

Clinical features from OMIM:


UMLS symptoms related to Lung Cancer:

fever, dyspnea, hemoptysis, snoring, coughing

GenomeRNAi Phenotypes related to Lung Cancer according to GeneCards Suite gene sharing:

26 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.01 BRAF KRAS EGFR PIK3CA
2 Decreased viability GR00106-A-0 11.01 KRAS
3 Decreased viability GR00221-A-1 11.01 KIT KRAS EGFR PIK3CA ALK NRAS
4 Decreased viability GR00221-A-2 11.01 KRAS MAP3K8 PIK3CA
5 Decreased viability GR00221-A-3 11.01 MAP3K8 NRAS ERBB2
6 Decreased viability GR00221-A-4 11.01 BRAF MAP3K8 EGFR PIK3CA ALK ERBB2
7 Decreased viability GR00301-A 11.01 BRAF KIT KRAS MAP3K8
8 Decreased viability GR00342-S-1 11.01 MAP3K8
9 Decreased viability GR00342-S-2 11.01 MAP3K8
10 Decreased viability GR00342-S-3 11.01 MAP3K8
11 Decreased viability GR00381-A-1 11.01 BRAF KRAS
12 Decreased viability GR00402-S-2 11.01 BRAF KIT KRAS MAP3K8 EGFR PIK3CA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.4 KRAS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.4 KRAS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.4 PRKN
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.4 KRAS
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.4 MAP3K8
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.4 KIT KRAS MAP3K8 PRKN
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 10.4 KIT
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 10.4 KRAS
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.4 KRAS
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 10.4 KRAS MAP3K8
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.4 KRAS
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 10.4 KRAS PRKN
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.4 KRAS
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 10.4 KIT
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 10.4 KRAS
28 Decreased viability in esophageal squamous lineage GR00235-A 9.96 BRAF ERBB2 ERCC6 FASLG KIT KRAS
29 Decreased cell migration GR00055-A-1 9.85 ALK BRAF EGFR KRAS PIK3CA
30 Decreased substrate adherent cell growth GR00193-A-1 9.85 KIT
31 Decreased substrate adherent cell growth GR00193-A-2 9.85 ALK EGFR KIT MAP3K8
32 Decreased substrate adherent cell growth GR00193-A-4 9.85 KIT
33 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.83 EGFR ERBB2 MAP3K8 NRAS PTEN
34 Reduced mammosphere formation GR00396-S 9.5 BRAF EGFR FASLG KRAS MAP3K8 NRAS
35 Increased cell migration GR00055-A-3 9.46 BRAF EGFR KRAS PIK3CA
36 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CASP8 ERCC6 PRKN PTEN SLC22A18
37 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 BRAF CASP8 ERCC6 FASLG PRKN PTEN

MGI Mouse Phenotypes related to Lung Cancer:

45 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 BRAF CASP8 EGFR ERBB2 ERCC6 FASLG
2 cardiovascular system MP:0005385 10.47 BRAF CASP8 EGFR ERBB2 FASLG IRF1
3 growth/size/body region MP:0005378 10.46 ALK BRAF CASP8 EGFR ERBB2 ERCC6
4 homeostasis/metabolism MP:0005376 10.46 ALK BRAF CASP8 EGFR ERBB2 ERCC6
5 integument MP:0010771 10.41 ALK BRAF CASP8 EGFR ERBB2 ERCC6
6 endocrine/exocrine gland MP:0005379 10.4 ALK BRAF CASP8 EGFR ERBB2 FASLG
7 mortality/aging MP:0010768 10.4 ALK BRAF CASP8 EGFR ERBB2 ERCC6
8 immune system MP:0005387 10.33 BRAF CASP8 EGFR ERCC6 FASLG IRF1
9 neoplasm MP:0002006 10.33 ALK BRAF CASP8 EGFR ERBB2 ERCC6
10 hematopoietic system MP:0005397 10.31 BRAF CASP8 EGFR ERCC6 FASLG IRF1
11 digestive/alimentary MP:0005381 10.3 BRAF EGFR ERBB2 FASLG KIT KRAS
12 embryo MP:0005380 10.3 BRAF CASP8 EGFR ERBB2 KIT KRAS
13 nervous system MP:0003631 10.25 ALK BRAF CASP8 EGFR ERBB2 ERCC6
14 craniofacial MP:0005382 10.21 BRAF EGFR ERBB2 KIT KRAS MAP2K1
15 muscle MP:0005369 10.18 BRAF CASP8 EGFR ERBB2 ERCC6 KIT
16 liver/biliary system MP:0005370 10.16 BRAF CASP8 EGFR ERCC6 FASLG KIT
17 normal MP:0002873 10.14 BRAF EGFR ERBB2 FASLG IRF1 KIT
18 limbs/digits/tail MP:0005371 10.13 BRAF EGFR ERBB2 ERCC6 KIT KRAS
19 hearing/vestibular/ear MP:0005377 10.05 BRAF EGFR ERCC6 KIT KRAS MAP2K1
20 reproductive system MP:0005389 10 ALK BRAF EGFR ERBB2 FASLG KIT
21 renal/urinary system MP:0005367 9.92 BRAF CASP8 EGFR FASLG IRF1 KIT
22 pigmentation MP:0001186 9.91 ALK BRAF EGFR KIT KRAS NRAS
23 respiratory system MP:0005388 9.85 ALK BRAF CASP8 EGFR ERBB2 FASLG
24 skeleton MP:0005390 9.83 ALK BRAF EGFR ERBB2 ERCC6 FASLG
25 vision/eye MP:0005391 9.36 ALK BRAF EGFR ERCC6 FASLG KIT

Drugs & Therapeutics for Lung Cancer

Drugs for Lung Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 903)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Iodine Approved, Investigational Phase 4 7553-56-2 807
Terbutaline Approved Phase 4 23031-25-6 5403
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Nicotine Approved Phase 4 54-11-5 942 89594
Dalteparin Approved Phase 4 9005-49-6
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
Budesonide Approved Phase 4 51333-22-3 63006 5281004
Caffeine Approved Phase 4 58-08-2 2519
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 5595
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
Norepinephrine Approved Phase 4 51-41-2 439260
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Remifentanil Approved Phase 4 132875-61-7 60815
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
Acetaminophen Approved Phase 4 103-90-2 1983
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
Etoposide Approved Phase 4 33419-42-0 36462
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
Fosaprepitant Approved Phase 4 172673-20-0 219090
Ondansetron Approved Phase 4 99614-02-5 4595
Flurbiprofen Approved, Investigational Phase 4 5104-49-4 3394
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
Epicatechin Investigational Phase 4 490-46-0, 35323-91-2 72276
Theobromine Investigational Phase 4 83-67-0 5429
38 Flurbiprofen axetil Investigational Phase 4 91503-79-6
39 Anti-Infective Agents, Local Phase 4
40 cadexomer iodine Phase 4
Salmeterol xinafoate Phase 4 94749-08-3 56801
42 Fluticasone-Salmeterol Drug Combination Phase 4
43 Central Nervous System Stimulants Phase 4
44 Phosphodiesterase Inhibitors Phase 4
45 Hypolipidemic Agents Phase 4
46 Lipid Regulating Agents Phase 4
Bilirubin Phase 4 635-65-4, 69853-43-6 5280352 21252250
48 Anticholesteremic Agents Phase 4
49 N-monoacetylcystine Phase 4
50 Expectorants Phase 4

Interventional clinical trials:

(show top 50) (show all 7986)
# Name Status NCT ID Phase Drugs
1 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
2 High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study Unknown status NCT02404675 Phase 4 icotinib
3 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
4 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
5 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
6 An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation Unknown status NCT01646450 Phase 4 Icotinib
7 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
8 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
9 A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
10 A Double Blind , Randomized, Multicenter Study of Second Line Treatment of Endostar(rh Recombined Endostatin)With Single Docetaxel In NSCLC Patients Unknown status NCT00813332 Phase 4 Endostar(rh recombinant endostatin) plus Docetaxel;Placebo plus Docetaxel
11 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
12 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
13 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
14 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
15 The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer Unknown status NCT02346318 Phase 4 Compound Kushen Injection
16 Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function Unknown status NCT02103244 Phase 4 Carboplatin
17 A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia Unknown status NCT02553187 Phase 4 Kanglaite Injection
18 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
19 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
20 Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
21 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
22 Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients Unknown status NCT02275702 Phase 4 Dexamethasone IV;Saline solution
23 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
24 Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
25 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
26 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01657487 Phase 4 Fluticasone/Salmeterol high dose
27 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Relapse and Metastasis of Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
28 Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients Unknown status NCT02547558 Phase 4 Indacaterol
29 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
30 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
31 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
32 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
33 A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients Completed NCT00608868 Phase 4 Gefitinib
34 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
35 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
36 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
37 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib
38 Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
39 A Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Completed NCT01287754 Phase 4 erlotinib [Tarceva]
40 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
41 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
42 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
43 An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy Completed NCT02208843 Phase 4 Afatinib
44 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
45 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
46 A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan Completed NCT01196078 Phase 4 erlotinib [Tarceva];vinorelbine
47 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
48 A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations Completed NCT02514174 Phase 4 Afatinib
49 Ensure Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva®) and Erlotinib After the Time of Disease Progression in Chinese Population Enrolled in the Ensure Trial Completed NCT02000531 Phase 4 Erlotinib;Chemotherapy
50 Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)

Search NIH Clinical Center for Lung Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :

afatinib dimaleate
etoposide phosphate
Irinotecan hydrochloride
Methotrexate Sodium
Procarbazine Hydrochloride
Topotecan Hydrochloride
Vinblastine Sulfate
Vinorelbine tartrate

Cochrane evidence based reviews: carcinoma, non-small-cell lung

Genetic Tests for Lung Cancer

Genetic tests related to Lung Cancer:

# Genetic test Affiliating Genes
1 Non-Small Cell Lung Cancer 29
3 Lung Cancer, Protection Against 29
4 Alveolar Cell Carcinoma 29
5 Neoplasm of Lung 29

Anatomical Context for Lung Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Lung Cancer:


MalaCards organs/tissues related to Lung Cancer:

Lung, Brain, Breast, Lymph Node, Testes, T Cells, Bone

Publications for Lung Cancer

Articles related to Lung Cancer:

(show top 50) (show all 59137)
# Title Authors PMID Year
CYP2A6 gene deletion reduces susceptibility to lung cancer. 54 61 56 6
10441482 1999
Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. 54 56 6
15937082 2005
Lung cancer: intragenic ERBB2 kinase mutations in tumours. 61 56 6
15457249 2004
Missense mutations of the BRAF gene in human lung adenocarcinoma. 54 56 6
12460919 2002
A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. 56 6
17450141 2007
High frequency of mutations of the PIK3CA gene in human cancers. 56 6
15016963 2004
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. 56 6
11745231 2001
Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. 56 6
10217419 1999
Screening for epidermal growth factor receptor mutations in lung cancer. 54 61 56
19692684 2009
LKB1 modulates lung cancer differentiation and metastasis. 54 61 56
17676035 2007
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. 54 61 56
17625570 2007
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. 54 61 56
15118073 2004
BRAF and RAS mutations in human lung cancer and melanoma. 54 61 6
12460918 2002
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. 61 56
25301630 2014
Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. 61 6
24846033 2014
National Working Group Meeting on ALK diagnostics in lung cancer. 61 6
24673736 2014
C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer. 61 56
21499297 2011
MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). 54 61 46
20223231 2010
MicroRNA-183 regulates Ezrin expression in lung cancer cells. 54 61 46
18840437 2008
Lung cancer. 61 56
18815398 2008
Detection of mutations in EGFR in circulating lung-cancer cells. 61 56
18596266 2008
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. 54 61 46
18246122 2008
DNA methylation markers and early recurrence in stage I lung cancer. 54 56
18337602 2008
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. 54 56
17463250 2007
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 54 6
15608678 2005
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. 54 56
15329413 2004
Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. 54 56
12802680 2003
Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. 54 56
10580025 1999
Association between the p21 codon 31 A1 (arg) allele and lung cancer. 54 56
8807325 1996
Genetic component of lung cancer: cohort study of twins. 61 56
7914565 1994
Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer. 61 42
31630262 2019
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. 6
31666701 2019
Targeted therapies for ROS1-rearranged non-small cell lung cancer. 61 42
31720561 2019
Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy. 61 42
31626089 2019
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 6
26266975 2015
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 6
26266985 2015
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. 6
25311215 2014
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. 56
25301631 2014
Comprehensive molecular profiling of lung adenocarcinoma. 56
25079552 2014
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. 6
24868098 2014
Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group. 6
24627688 2014
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. 6
23562183 2013
Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group. 6
23667368 2013
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 6
23100325 2013
Comprehensive genomic characterization of squamous cell lung cancers. 56
22960745 2012
A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer. 56
22883146 2012
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. 56
22751098 2012
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 6
22658544 2012
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. 6
22729223 2012
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. 6
22729224 2012

Variations for Lung Cancer

ClinVar genetic disease variations for Lung Cancer:

6 (show top 50) (show all 256) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CASP8 NM_001228.4(CASP8):c.-937_-932deldeletion protective 7763 rs3834129 2:202097532-202097537 2:201232809-201232814
2 CYP2A6 CYP2A6*4Adeletion protective 16970
3 EGFR NM_005228.5(EGFR):c.2155G>C (p.Gly719Arg)SNV Likely pathogenic,drug response 45224 rs28929495 7:55241707-55241707 7:55174014-55174014
4 EGFR NM_005228.5(EGFR):c.2156G>C (p.Gly719Ala)SNV Pathogenic 45225 rs121913428 7:55241708-55241708 7:55174015-55174015
5 EGFR NM_005228.5(EGFR):c.2127_2129del (p.Glu709_Thr710delinsAsp)deletion Pathogenic 45220 rs397517086 7:55241679-55241681 7:55173986-55173988
6 EGFR NM_005228.5(EGFR):c.2310_2311insGGGTTG (p.Asn771_Pro772insGlyLeu)insertion Pathogenic 45257 rs397517111 7:55249012-55249013 7:55181319-55181320
7 EGFR NM_005228.5(EGFR):c.2312_2314dup (p.Pro772_His773insHis)duplication Pathogenic 45258 rs397517112 7:55249013-55249014 7:55181320-55181321
8 EGFR NM_005228.5(EGFR):c.2303G>T (p.Ser768Ile)SNV Pathogenic 45251 rs121913465 7:55249005-55249005 7:55181312-55181312
9 EGFR NM_005228.5(EGFR):c.2303_2304delinsTT (p.Ser768Ile)indel Pathogenic 45252 rs397517108 7:55249005-55249006 7:55181312-55181313
10 EGFR NM_005228.5(EGFR):c.2500G>T (p.Val834Leu)SNV Pathogenic 45279 rs397517127 7:55259442-55259442 7:55191749-55191749
11 BRAF NM_004333.6(BRAF):c.1405_1407del (p.Gly469del)deletion Pathogenic 44802 rs397516890 7:140481401-140481403 7:140781601-140781603
12 BRAF NM_004333.6(BRAF):c.1406G>T (p.Gly469Val)SNV Pathogenic 44803 rs121913355 7:140481402-140481402 7:140781602-140781602
13 KRAS NM_033360.4(KRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 45115 rs121913240 12:25380276-25380276 12:25227342-25227342
14 KRAS NM_033360.4(KRAS):c.182A>T (p.Gln61Leu)SNV Pathogenic 45116 rs121913240 12:25380276-25380276 12:25227342-25227342
15 ERBB2 NM_004448.3(ERBB2):c.2331_2339dup (p.Gly778_Pro780dup)duplication Pathogenic 44992 rs397516981 17:37881001-37881002 17:39724748-39724749
16 KRAS NM_033360.4(KRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 45123 rs121913535 12:25398282-25398282 12:25245348-25245348
17 PIK3CA NM_006218.4(PIK3CA):c.3073A>G (p.Thr1025Ala)SNV Pathogenic 45467 rs397517202 3:178952018-178952018 3:179234230-179234230
18 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
19 NRAS NM_002524.5(NRAS):c.35G>A (p.Gly12Asp)SNV Pathogenic 39648 rs121913237 1:115258747-115258747 1:114716126-114716126
20 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
21 BRAF NM_004333.6(BRAF):c.735A>C (p.Leu245Phe)SNV Pathogenic 40347 rs397507466 7:140501337-140501337 7:140801537-140801537
22 NRAS NM_002524.5(NRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 40468 rs121913250 1:115258748-115258748 1:114716127-114716127
23 NRAS NM_002524.5(NRAS):c.34G>C (p.Gly12Arg)SNV Pathogenic 40469 rs121913250 1:115258748-115258748 1:114716127-114716127
24 MAP2K1 NM_002755.3(MAP2K1):c.199G>A (p.Asp67Asn)SNV Pathogenic 40781 rs727504317 15:66727483-66727483 15:66435145-66435145
25 PTEN NM_000314.7(PTEN):c.697C>T (p.Arg233Ter)SNV Pathogenic 7813 rs121909219 10:89717672-89717672 10:87957915-87957915
26 PPP2R1B NM_002716.5(PPP2R1B):c.269G>A (p.Gly90Asp)SNV Pathogenic 6621 rs1805076 11:111635566-111635566 11:111764842-111764842
27 SLC22A18 NM_002555.6(SLC22A18):c.698C>T (p.Ser233Phe)SNV Pathogenic 6978 rs121909071 11:2939260-2939260 11:2918030-2918030
28 PRKN NM_004562.3(PRKN):c.823C>T (p.Arg275Trp)SNV Pathogenic 7050 rs34424986 6:162206852-162206852 6:161785820-161785820
29 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
30 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu)SNV Pathogenic 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
31 BRAF NM_004333.6(BRAF):c.1801A>G (p.Lys601Glu)SNV Pathogenic 13966 rs121913364 7:140453134-140453134 7:140753334-140753334
32 BRAF NM_004333.6(BRAF):c.1789C>G (p.Leu597Val)SNV Pathogenic 13969 rs121913369 7:140453146-140453146 7:140753346-140753346
33 BRAF NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala)SNV Pathogenic 13971 rs121913355 7:140481402-140481402 7:140781602-140781602
34 BRAF NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly)SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354
35 IRF1 NM_002198.3(IRF1):c.31T>C (p.Trp11Arg)SNV Pathogenic 14721 rs121912470 5:131825140-131825140 5:132489448-132489448
36 NRAS NM_002524.5(NRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 177778 rs121913250 1:115258748-115258748 1:114716127-114716127
37 KRAS NM_033360.4(KRAS):c.181C>A (p.Gln61Lys)SNV Pathogenic 177777 rs121913238 12:25380277-25380277 12:25227343-25227343
38 KRAS NM_033360.4(KRAS):c.179G>T (p.Gly60Val)SNV Pathogenic 163766 rs727503108 12:25380279-25380279 12:25227345-25227345
39 ERCC6 NM_000124.4(ERCC6):c.2830-2A>GSNV Pathogenic 190163 rs373227647 10:50680518-50680518 10:49472472-49472472
40 BRAF NM_004333.6(BRAF):c.1794_1796dup (p.Thr599dup)duplication Pathogenic 162793 rs727502902 7:140453138-140453139 7:140753338-140753339
41 NRAS NM_002524.5(NRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 219097 rs121913237 1:115258747-115258747 1:114716126-114716126
42 ERCC6 NM_000124.4(ERCC6):c.2203C>T (p.Arg735Ter)SNV Pathogenic 1701 rs121917901 10:50686483-50686483 10:49478437-49478437
43 ERCC6 NM_000124.4(ERCC6):c.1357C>T (p.Arg453Ter)SNV Pathogenic 1703 rs121917902 10:50732119-50732119 10:49524073-49524073
44 KRAS NM_033360.4(KRAS):c.34G>C (p.Gly12Arg)SNV Pathogenic 12579 rs121913530 12:25398285-25398285 12:25245351-25245351
45 KRAS NM_033360.4(KRAS):c.38G>A (p.Gly13Asp)SNV Pathogenic 12580 rs112445441 12:25398281-25398281 12:25245347-25245347
46 KRAS NM_004985.5(KRAS):c.35G>A (p.Gly12Asp)SNV Pathogenic 12582 rs121913529 12:25398284-25398284 12:25245350-25245350
47 KRAS NM_004985.5(KRAS):c.35G>T (p.Gly12Val)SNV Pathogenic 12583 rs121913529 12:25398284-25398284 12:25245350-25245350
48 KRAS NM_033360.4(KRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12584 rs121913530 12:25398285-25398285 12:25245351-25245351
49 KRAS NM_033360.4(KRAS):c.*12A>TSNV Pathogenic 12587 rs104894360 12:25362838-25362838 12:25209904-25209904
50 KRAS NM_033360.4(KRAS):c.37G>C (p.Gly13Arg)SNV Pa